Answer
After intramuscular injection, Spikevax LP.8.1 delivers lipid-encapsulated mRNA into cells to produce SARS-CoV-2 spike protein, which immune cells recognise as foreign, triggering T-cell and B-cell responses and neutralising antibodies that may contribute to protection against COVID-19.
Sources for this answer
- Spikevax LP.8.1Moderna Biotech Distributor UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 1Document updated
Sources checked